Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of lumacaftor + ivacaftor in cystic fibrosis with homozygous F508del CFTR mutation
2012-003990-24Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lumacaftor, ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Mar 2013; status: completed.
02
Drugs
lumacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2012-003990-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003990-24.